European Medicines Agency
Veterinary Medicines and Inspections

London, 17 July 2009
Doc. Ref.: EMEA/CVMP/409781/2009

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
SUMMARY OF OPINION*
MELOXIDYL

International Non-proprietary Name (INN):
Meloxicam

On 15 July 2009, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion,** recommending to grant an extension to the terms of the marketing authorisation for the veterinary medicinal product MELOXIDYL.The Marketing Authorisation Holder for this product is CEVA Santé Animale.

The change agreed by the CVMP concerns a new pharmaceutical form, 5mg/ml solution for injection for dogs and cats.

The approved indication in dogs for MELOXIDYL 5 mg/ml solution for injection is alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders and the reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery. The approved indication in cats is the reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

Detailed conditions for the use of this product will be described in the Summary of Product Characteristics (SPC) which will be published in the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the extension to the marketing authorisation has been granted by the European Commission.

* Summaries of opinion are published without prejudice to the Commission Decision, which will normally be issued within 90 days from adoption of the Opinion.

** Applicants may appeal any CVMP opinion, provided they notify the EMEA in writing of their intention to appeal within 15 days of receipt of the opinion.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 47
E-mail: mail@emea.europa.eu http://www.emea.europa.eu